Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Axsome Therapeutics's Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-3,361 Mil. Therefore, Axsome Therapeutics's EV-to-EBIT ratio for today is -60.80.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Axsome Therapeutics's Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-3,190 Mil. Therefore, Axsome Therapeutics's EV-to-EBITDA ratio for today is -64.04.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Axsome Therapeutics's Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN12,939 Mil. Therefore, Axsome Therapeutics's EV-to-Revenue ratio for today is 15.79.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Axsome Therapeutics (MEX:AZSM) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Axsome Therapeutics's current Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-3,361 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Axsome Therapeutics's current Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-3,190 Mil.
Axsome Therapeutics's current Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN12,939 Mil.
Axsome Therapeutics's current Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,300 Mil.
Axsome Therapeutics's current Enterprise Value is MXN204,308 Mil.
Axsome Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,305 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics Enterprise Value Related Terms
Axsome Therapeutics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AZSM vs MDGL, IONS, BMRN: Enterprise Value Comparison
For the Biotechnology subindustry, Axsome Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Axsome Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN204,308 Mil mean?
Axsome Therapeutics (MEX:AZSM) has a Enterprise Value of MXN204,308 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Enterprise Value too high?
Axsome Therapeutics' current Enterprise Value is MXN204,308 Mil. Overall, Axsome Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Enterprise Value compare to MDGL and IONS?
Axsome Therapeutics' Enterprise Value of MXN204,308 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Enterprise Value is MXN204,308 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Axsome Therapeutics (MEX:AZSM) has a current Enterprise Value of MXN204,308 Mil. The stock's GF Value™ is MXN1,494.25, compared to a current price of MXN1,519.00 — trading 1.7% above its estimated fair value. The current Enterprise Value is MXN204,308 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Axsome Therapeutics (MEX:AZSM), the current Enterprise Value is MXN204,308 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (MEX:AZSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of MXN1,519.00 is trading 1.7% above its estimated GF Value™ of MXN1,494.25.
Key valuation signals for MEX:AZSM:
Enterprise Value: MXN204,308 Mil
GF Value™: MXN1,494.25 vs. price of MXN1,519.00 (1.7% above fair value)
No single metric tells the full story. See the MEX:AZSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for MEX:AZSM
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AZSM has been successfully added to your 
